Original Article
Association of ALDH2 rs671 polymorphism with essential hypertension: a case-control study in non-drinking Han Chinese

Lili Zhang, Limei Dong, Qian Ma, Guocai Yang

Department of Cardiology, The People’ Hospital of Rizhao, Rizhao 276800, Shandong, China
Received November 27, 2015; Accepted August 14, 2016; Epub June 15, 2018; Published June 30, 2018

Abstract: Objective: This study was aimed to investigate the association of acetaldehyde dehydrogenase 2 (ALDH2) rs671 polymorphism with the risk of essential hypertension (EH). Methods: 137 EH patients and 102 healthy individuals in Chinese Han population were selected as the study subjects. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was applied to detect ALDH2 rs671 polymorphism. Association between ALDH2 rs671 polymorphism and EH risk was calculated by Chi-square test. Risk intensity of EH was represented by odds ratios (ORs) and 95% confidence intervals (CIs). Results: Systolic blood pressure (SBP), diastolic blood pressure (DBP) and total cholesterol (TC) had high levels in cases than that in controls (P<0.05), while other characteristics had no significant difference between the two groups. AA genotype and A allele of rs671 might increase the risk of EH (P=0.023, OR=3.195, 95% CI=1.128-9.049; P=0.013, OR=1.759, 95% CI=1.124-2.751). After adjusted by age, SBP, DBP, body mass index (BMI), triglyceride (TG) and TC, the association had no obvious change (P=0.040, OR=3.402, 95% CI=1.037-1.824; P=0.028, OR=1.853, 95% CI=1.142-3.045). Conclusions: ALDH2 rs671 polymorphism might act as a risk factor for the onset of EH in non-drinking Han Chinese.

Keywords: Essential hypertension (EH), acetaldehyde dehydrogenase 2 (ALDH2), polymorphism

Introduction
Essential hypertension (EH) and secondary hypertension are the main types of hypertension, and the former accounts the most part of the hypertension cases. EH is a quite common cardiovascular disease (CVD) at present. By definition, EH has no recognizable cause. However, several risk factors have been identified. It is reported that EH is greatly affected by genetic and environmental factors [1-6], and the genetic factor play a critical role in the onset of EH [7, 8]. The high morbidity and mortality of stroke, coronary artery disease (CAD) and diabetes caused by EH immensely increase the economic burden of society and government. Blood pressure control is an important measure to prevent the high incidence of CVD at the moment [9]. However, EH is a lifelong disease, the blood pressure can be controlled, but the EH cannot be cured. In order to improve the therapy method of EH, the exploration of the EH mechanism is necessary. Up to now, many genes are found to be associated with the risk of EH.

Acetaldehyde dehydrogenase (ALDH) is a big family composed of various isozymes. ALDH2, the most important member of ALDH family, is one of the key enzymes of ethanol metabolism in the human body [10]. ALDH2 mainly expressed in mitochondria. Human ALDH2 gene locates at 12q24.2, and contains 13 exons and 12 introns [11]. Single nucleotide polymorphism (SNP) which is in the 12th exon led to a missense mutation (Glu to Lys) in the 504 site. This SNP, namely rs671 (also known as ALDH2*2), plays an important role in the connection structure of coenzyme binding site. This mutation makes the ALDH2 loses the ability of combination of coenzyme, and causes the loss of enzyme activity [12]. ALDH2 is a protector for oxidative stress [13, 14]. The decrease of ALDH2 enzyme activity can increase the oxidative stress inside the body. The research of ALDH2 gene polymorphism mainly
focused on rs671, and several studies detect the association between rs671 and the risk of EH [15-17]. Distinctly genetic polymorphism exists in ALDH2 gene. Meanwhile, the reports are not consistent about the correlation between ALDH2 polymorphism and the incidence of EH up to now.

So, in present study, we select ALDH2 rs671 polymorphism to analyze the association of ALDH2 polymorphism with EH. This study will contribute to the prevention, treatment and prognosis of clinical CVD.

Materials and methods

Research objects

This study was approved by the ethics committee of The People’ Hospital of Rizhao, Informed consents were signed by every participant. 239 unrelated Han Chinese population were recruited from out-patient clinics, in-patient department and physical examination center of The People’ Hospital of Rizhao from April, 2013 to April, 2015. Among them were 137 EH patients with the age range of 36-80 years old as the case group and the rest were 102 healthy people from 33 to 76 years old as the control group, respectively. EH patients were diagnosed based on 2011 China guidelines for the diagnosis and treatment of hypertension: systolic blood pressure (SBP) ≥140 mmHg and (or) diastolic blood pressure (DBP) ≥90 mmHg, continuously or more than 3 times at sitting position, in three different days. Drinkers, patients with secondary hypertension, serious cardiac insufficiency and clear kidney lesion were excluded from this study.

Sample collection

5 ml peripheral venous blood was extracted from every fasting participator, anticoagulated by EDTA-Na$_2$, and then stored in -70°C for back-up. Genomic DNA was extracted by a GenElute™ Blood Genomic DNA Kit (Sigma, USA).

DNA products amplified by polymerase chain reaction (PCR)

PCR primers of ALDH2 rs671 SNP were designed by Primer Premier 5.0 software and synthesized by Boya biological technology co., LTD (Shanghai, China). Forward primer was 5'-GTC AAC TGC TAT GAT GTG TTT GG-3', reverse primer was 5'-CCA CCA GCA GAC CCT CAA G-3', and PCR amplified fragments were 91 bp. PCR amplification system was 25 μL, including 1 μL template DNA, 2.5 pmol primers, 0.25 mM 4× dNTP, 2.5 mM MgCl$_2$, 1 uL Taq enzyme and 2.5 μL 10× Buffer. Amplification conditions were as follows: 95°C pre-degeneration for 10 min; then followed by 35 cycles of 95°C degeneration for 1 min, 58°C annealing for 2 min, 72°C extension for 1 min; finally 72°C extension for 5 min. After the amplification, 3 μL PCR products were added into 5vMbo II restriction enzyme and 10× L Buffer which with the total volume was 10 μL, and the mixture was digested at 37°C for 2.5 h. 8 μL digested products were analyzed by 15% polyacrylamide gel electrophoresis and ethidium bromide staining. Three genotypes were presented under ultraviolet radiation: wild homozygote GG with a 55 bp stripe, heterozygote GA with 65 bp and 55 bp stripes and mutant homozygote AA with a 65 bp stripe.

Determination of blood lipid level

The levels of total cholesterol (TC) and triglycerides (TG) were examined by automatic biochemical analyzer (Olympus 1000 type, USA) in accordance with the kit instructions.

Statistical analysis

SPSS18.0 was applied to analyze all of the experimental data. Differences of clinical characteristics between groups were compared by χ² test or t test. Hardy-Weinberg equilibrium (HWE) was used to evaluate the genotype distributions. When P>0.05, genotype distribution conformed to HWE. Genotypes and alleles differences between cases and controls were calculated by χ² test, and then adjusted by logistic regression. The relative risk was expressed by odds ratios (ORs) as well as 95% confidence intervals (CIs). P<0.05 stood for statistically significant difference.

Results

General clinical features of study objects

In the case group are 90 males and 47 females with the mean age of 65.12±11.24, and the
ALDH2 polymorphism and essential hypertension

controls consisted of 67 males and 35 females with an average age of 66.18±10.32. There was no significant difference in age and gender distributions between the two groups (P>0.05). Body mass index (BMI) in the two groups was 26.1±3.4 and 25.2±3.2 respectively and the difference was not obvious (P>0.05). SBP (161.5±15.3, 120.2±11.4), DBP (95.4±12.6, 81.5±10.6) and TC (4.9±1.2, 4.6±1.1) levels in the case group were all significantly higher than that in the control group (P<0.05), but TG level was not significant difference between the two (1.7±1.1, 1.5±0.9; P>0.05). The detailed data were list in Table 1.

### Table 1. General clinical characteristics of case and control groups

<table>
<thead>
<tr>
<th>Group</th>
<th>Gender (male/female)</th>
<th>Age (mean±SD)</th>
<th>SBP (mmHg)</th>
<th>DBP (mmHg)</th>
<th>BMI (kg/m²)</th>
<th>TC (mmol/L)</th>
<th>TG (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case</td>
<td>90/47</td>
<td>65.12±11.24</td>
<td>161.5±15.3</td>
<td>95.4±12.6</td>
<td>26.1±3.5</td>
<td>4.9±1.2</td>
<td>1.7±1.1</td>
</tr>
<tr>
<td>Control</td>
<td>67/35</td>
<td>66.18±10.32</td>
<td>120.2±11.4</td>
<td>81.5±10.6</td>
<td>25.2±3.2</td>
<td>4.6±1.1</td>
<td>1.5±0.9</td>
</tr>
<tr>
<td>P</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&lt;0.05</td>
<td>&lt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index; TC: Cholesterol; TG: Triglycerides.

### Table 2. Distributions of ALDH2 rs671 polymorphism in case and control groups

<table>
<thead>
<tr>
<th>Genotype/Allele</th>
<th>Case n=137</th>
<th>Control n=102</th>
<th>P</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>OR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs671</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>80 (58.39)</td>
<td>71 (69.61)</td>
<td>-</td>
<td>1.00</td>
<td>-</td>
<td>1.00</td>
</tr>
<tr>
<td>GA</td>
<td>39 (28.47)</td>
<td>26 (25.49)</td>
<td>0.341</td>
<td>1.331 (0.738-2.402)</td>
<td>0.372</td>
<td>1.507 (0.891-3.688)</td>
</tr>
<tr>
<td>AA</td>
<td>18 (13.14)</td>
<td>5 (4.90)</td>
<td>0.023</td>
<td>3.195 (1.128-9.049)</td>
<td>0.040</td>
<td>3.402 (1.037-2.824)</td>
</tr>
<tr>
<td>G</td>
<td>199 (72.63)</td>
<td>168 (82.35)</td>
<td>-</td>
<td>1.00</td>
<td>-</td>
<td>1.00</td>
</tr>
<tr>
<td>A</td>
<td>75 (27.37)</td>
<td>36 (17.65)</td>
<td>0.013</td>
<td>1.759 (1.124-2.751)</td>
<td>0.028</td>
<td>1.853 (1.142-3.045)</td>
</tr>
<tr>
<td>P_HWE</td>
<td>0.001</td>
<td>0.214</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: OR*: OR adjusted by age, SBP, DBP, BMI, TG and TC.

Correlation analysis between ALDH2 rs671 polymorphism and EH risk

The genotype and allele frequencies of ALDH2 rs671 polymorphism in the case and control groups were compared and showed in Table 2. Firstly, genotype distribution of ALDH2 rs671 polymorphism in control group conformed to HWE test (P>0.05), indicating the representativeness of the study population.

AA genotype of rs671 had higher frequency in case group than that in control group (13.14% vs. 4.90%), this difference was statistically significant (P=0.023). The result indicated that the AA genotype increase the risk of EH (OR=3.195, 95% CI=1.128-9.049). After the adjustments of confounding factors like age, SBP, DBP, BMI, TG and TC, AA genotype still associated with the risk of EH (OR=3.402, 95% CI=1.037-1.824). Meanwhile, the frequency of A allele was significantly different between cases and controls (P=0.013). The A allele significantly increased the risk of EH before (OR=1.759, 95% CI=1.124-2.751) and after (OR=1.853, 95% CI=1.142-3.045) the adjustment of confounding factors. However, although GA genotype had high frequency in cases, but the association with EH risk had no significance (P>0.05).

Discussion

Hypertension means the increase of SBP and/or DBP of arteries in the quiescent condition. Hypertension is a systemic disease accompanied with functional or organic changes of many organ, and lead to many complications. With the unidentifiable cause, EH has a high morbidity, and the pathogenesis of it is not yet clear. Most part of the EH is a chronic CVD, the features of it are hidden onset, slow progress, and long duration. Complications of EH might lead to sudden death. Besides, the control of EH could affect the development of many cardiovascular and cerebrovascular diseases [18, 19]. Multiple researches revealed that alcoholism is a risk factor for CVD, including EH [10-
ALDH2 polymorphism and essential hypertension

EH related genome-wide association studies manifested that ALDH2 may affect the changes of SBP and DBP through changing the alcohol consumption and blood lipid metabolism [17, 23, 24]. ALDH2 is the key enzyme in oxidative stress and alcohol metabolism [13, 25]. Besides, ALDH2 also influences the levels of TG and high-density-lipoprotein cholesterol (HDLc) [26]. Amamoto et al. have found that GG genotype of rs671 is a risk factor of EH, and the blood pressure increases in the sequence of GG>GA>AA [27]. Moreover, Lai et al. showed that ALDH2 mutant genotype is an independent risk factor for EH, and it is able to increase the risk of concurrent acute CVD events in EH patients through elevating the blood pressure [28].

ALDH2 widely distributes in human organs such as liver, kidney, heart, lungs and brain. ALDH2 rs671 polymorphism, which has racial difference, is the site that has been studied most. Additionally, human genome project (HGP) illustrated that rs671 polymorphism is common in Asians, but rare and even not distributes in white and black races. ALDH2 polymorphism of people in the same race from different regions also has significant differences [20].

Present study discovered that the frequency of rs671 A allele is 27.37% in cases and 17.65% in controls, respectively. Meanwhile, AA and GA genotypes of rs671 were higher in cases than in controls. Our results demonstrated that AA genotype and A allele might increase the risk of EH about 3.195 and 1.759 times. Logistic regression indicated that, after adjusted by confounding factors (including age, SBP, DBP, BMI, TG and TC), AA genotype and A allele were still able to increase the risk of EH. The association of AA genotype and A allele of rs671 with EH risk were significantly, revealing that ALDH2 rs671 polymorphism was a risk factor of EH. This result accorded with the previous study performed by Wang et al. [29]. However, another study showed that A allele decrease the EH risk in Chinese Han drinkers [15]. In Chinese Mongolia population, AA genotype was not found, and A allele might negatively associated with the EH risk [16]. It was reported that AA genotype of rs671 together with ADH1B rs1229984 could affect the drinking behavior, and rs671 significantly correlated with blood pressure in drinkers in Japanese [30]. These discrepant results might caused by the different ethnicity, study subjects and other reasons.

To sum up, ALDH2 rs671 polymorphism might be one of the genetic risk factors for the incidence of EH. But, the etiology and pathogenesis of EH remain unclear by far. Although the representativeness of our study is good, there still many limitations influence the accuracy of our result, such as the small sample size. In addition, the ethnicity number, stratified analysis and interaction with other factors are not considered in current study. Therefore, the specific mechanism of ALDH2 mutations inducing EH still needs to be studied. The further studies should expand the race number and sample size, and include stratified and interaction analysis.

Disclosure of conflict of interest

None.

Address correspondence to: Lili Zhang, Department of Cardiology, The People’ Hospital of Rizhao, Rizhao 276800, Shandong, China. E-mail: xhggsb55@126.com

References


ALDH2 polymorphism and essential hypertension


[27] Amamoto K, Okamura T, Tamaki S, Kita Y, Tsujita Y, Kadowaki T, Nakamura Y and Ueshima H. Epidemiologic study of the associ-
ALDH2 polymorphism and essential hypertension


